Literature DB >> 31076732

Manipulating the tumour-suppressor protein Rb in lung cancer reveals possible drug targets.

Seth M Rubin, Julien Sage.   

Abstract

Entities:  

Keywords:  Cancer; Medical research

Mesh：

Year:  2019        PMID： 31076732      PMCID： PMC7197376          DOI： 10.1038/d41586-019-01319-y

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  9 in total

Review 1.  CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.

Authors:  Mary E Klein; Marta Kovatcheva; Lara E Davis; William D Tap; Andrew Koff
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

2.  Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells.

Authors:  J C Donovan; A Milic; J M Slingerland
Journal:  J Biol Chem       Date:  2001-08-29       Impact factor: 5.157

3.  Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma.

Authors:  Brian P Rubin; Koichi Nishijo; Hung-I Harry Chen; Xiaolan Yi; David P Schuetze; Ranadip Pal; Suresh I Prajapati; Jinu Abraham; Benjamin R Arenkiel; Qing-Rong Chen; Sean Davis; Amanda T McCleish; Mario R Capecchi; Joel E Michalek; Lee Ann Zarzabal; Javed Khan; Zhongxin Yu; David M Parham; Frederic G Barr; Paul S Meltzer; Yidong Chen; Charles Keller
Journal:  Cancer Cell       Date:  2011-02-15       Impact factor: 31.743

4.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.

Authors:  Sheng Yu Ku; Spencer Rosario; Yanqing Wang; Ping Mu; Mukund Seshadri; Zachary W Goodrich; Maxwell M Goodrich; David P Labbé; Eduardo Cortes Gomez; Jianmin Wang; Henry W Long; Bo Xu; Myles Brown; Massimo Loda; Charles L Sawyers; Leigh Ellis; David W Goodrich
Journal:  Science       Date:  2017-01-06       Impact factor: 47.728

Review 5.  The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition.

Authors:  S Meloche; J Pouysségur
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

Review 6.  Deciphering the retinoblastoma protein phosphorylation code.

Authors:  Seth M Rubin
Journal:  Trends Biochem Sci       Date:  2012-12-03       Impact factor: 13.807

Review 7.  Crosstalk between stem cell and cell cycle machineries.

Authors:  Michael S Kareta; Julien Sage; Marius Wernig
Journal:  Curr Opin Cell Biol       Date:  2015-11-11       Impact factor: 8.382

8.  The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-Ras.

Authors:  V M Ho; B E Schaffer; A N Karnezis; K S Park; J Sage
Journal:  Oncogene       Date:  2009-01-19       Impact factor: 9.867

Review 9.  RB1: a prototype tumor suppressor and an enigma.

Authors:  Nicholas J Dyson
Journal:  Genes Dev       Date:  2016-07-01       Impact factor: 11.361
  9 in total
  4 in total

1.  The regulatory landscape of retinoblastoma: a pathway analysis perspective.

Authors:  Laura Gómez-Romero; Diana E Alvarez-Suarez; Enrique Hernández-Lemus; M Verónica Ponce-Castañeda; Hugo Tovar
Journal:  R Soc Open Sci       Date:  2022-05-18       Impact factor: 3.653

2.  CRISPR/Cas9 library screening uncovered methylated PKP2 as a critical driver of lung cancer radioresistance by stabilizing β-catenin.

Authors:  Chun Cheng; Xiaofeng Pei; Si-Wei Li; Jun Yang; Chenxi Li; Jianjun Tang; Kaishun Hu; Guofu Huang; Wei-Ping Min; Yi Sang
Journal:  Oncogene       Date:  2021-03-19       Impact factor: 9.867

3.  A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers.

Authors:  Masanori Kawakami; Lisa Maria Mustachio; Yulong Chen; Zibo Chen; Xiuxia Liu; Cheng-Hsin Wei; Jason Roszik; Adam S Kittai; Alexey V Danilov; Xiaoshan Zhang; Bingliang Fang; Jing Wang; John V Heymach; Liliya Tyutyunyk-Massey; Sarah J Freemantle; Jonathan M Kurie; Xi Liu; Ethan Dmitrovsky
Journal:  Mol Cancer Ther       Date:  2020-12-04       Impact factor: 6.261

4.  Identifying CpG methylation signature as a promising biomarker for recurrence and immunotherapy in non-small-cell lung carcinoma.

Authors:  Ruihan Luo; Jing Song; Xiao Xiao; Zhengbo Xie; Zhiyuan Zhao; Wanfeng Zhang; Shiqi Miao; Yongyao Tang; Longke Ran
Journal:  Aging (Albany NY)       Date:  2020-07-28       Impact factor: 5.682
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.